PharmaCyte Biotech
PMCB
32 hedge funds and large institutions have $2.35M invested in PharmaCyte Biotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
38% more call options, than puts
Call options by funds: $18K | Put options by funds: $13K
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
3% more funds holding
Funds holding: 31 → 32 (+1)
0.39% less ownership
Funds ownership: 13.02% → 12.63% (-0.39%)
2% less capital invested
Capital invested by funds: $2.4M → $2.35M (-$51.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$100K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.7K |
| 3 |
Squarepoint
New York
|
+$32.2K |
| 4 |
Renaissance Technologies
New York
|
+$11.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$32K |
| 2 |
BlackRock
New York
|
-$28.1K |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$27.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$14.7K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $30 | +$30 | +14 | New |
|
27
UBS Group
Zurich,
Switzerland
| $29 | +$9 | +4 | +44% |
|
28
JP Morgan Chase
New York
| $26 | -$11 | -5 | -29% |
|
29
Morgan Stanley
New York
| $18 | +$11 | +5 | +167% |
|
|
NA
30
NewEdge Advisors
New Orleans,
Louisiana
| $6 | – | – | – |
|
|
CL
31
CSS LLC
Chicago,
Illinois
| – | -$27.7K | -13,186 | Closed |
|
|
CWA
32
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
| – | -$4 | -2 | Closed |
|
|
C
33
Covestor
London,
United Kingdom
| – | +$80 | +37 | +20% |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$362 | +167 | +170% |
|
PMCB Hedge Fund Activity: Q4 2023 in Review
32 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q4 2023, worth a combined $2.35M — down 2.2% from $2.4M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PMCB positions and 3 closed out — a net gain of 2 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was K2 Principal Fund, adding an estimated $100K. The largest seller was Sabby Management, cutting an estimated $32K.
- 32 institutional investors held PharmaCyte Biotech (PMCB) as of Q4 2023, up from 31 in Q3 2023.
- Funds reported $2.35M of PharmaCyte Biotech stock for Q4 2023, down 2.2% quarter-over-quarter.
- 5 funds opened new PharmaCyte Biotech positions in Q4 2023 and 3 closed out, a net change of +2 holders.
- The largest PharmaCyte Biotech buyer in Q4 2023 was K2 Principal Fund, an estimated $100K added.
- The largest PharmaCyte Biotech seller in Q4 2023 was Sabby Management, an estimated $32K sold.
Based on aggregated 13F filings for Q4 2023.